27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
MediPharm Labs Corp. (OTC:MEDIF), a company that specializes in research-driven cannabis extraction and cannabinoid isolation, announced Thursday that is has gained conditional authorization to uplist from the Toronto Venture Exchange to the Toronto Stock Exchange, where it will list under the ticker symbol "LABS."
The company said it to meet certain requirements to secure final approval of the listing by July 23.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
“We are thrilled to have qualified to uplist to the TSX. This is an important step for the MediPharm Labs team and our shareholders,” CEO Patrick McCutcheon said in a statement.
“We have achieved significant growth and strong performance since we first began trading last October to become a top revenue-generating cannabis company in Canada. As we focus on executing an ambitious global growth strategy, this graduation will also allow us to expand our investor audience and improve the liquidity of our shares.”
MediPharm shares were trading higher by 2.31% to $3.67 at the time of publication Thursday.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.